Jonathan Lanfear News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of HC-5404 and Maps Forward Path as Monotherapy and in Combinations...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A ... | April 28, 2023

FDA's vaccines office is now headed by Peter Marks after the agency's top two vaccine officials questioned the need for booster doses last month as they head toward the exit later this fall. Houston biotech incubator Sporos Biosciences snagged ex-Ovid Therapeutics Chief Medical Officer Amit Rakhit as its new CEO. In spinning off its gene therapy unit, Amicus' CEO will head to the new company being launched via a SPAC.

Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi ... Coherus BioSciences, Inc.February 1, 2021 GMT - Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody - First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation - Options to PD-1 combination agents, TIGIT and IL-2, add long-term growth potential - Conference call at 8:00 ...